AH Equity Partners Bio II, L.L.C.

Related company / holding

EQRx, Inc.Nautilus Biotechnology, Inc.

Insider activity · 24 months0 buys2 salesCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 2 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Companies

▲ Purchases (0 ops.)

—

▼ Sales (2 ops.)

€10.1M

Latest filing published 04 Jun 2026 for Nautilus Biotechnology, Inc., €9.3M.

Filing timeline

BuySale

AH Equity Partners Bio II, L.L.C.

Insider track record

Disclosed buys

Disclosed sells

Signal history

AH Equity Partners Bio II, L.L.C.: trading record in brief

AH Equity Partners Bio II, L.L.C. has filed trades across 2 companies (mainly through SEC (Form 4)), most often in EQRx, Inc. and Nautilus Biotechnology, Inc. Over a trading history stretching from 9 November 2023 to 2 June 2026, the count stands at 7 filings.

No open-market purchase appears, only 2 sales worth €10.1M. In 2026 alone, the filings show no purchases and 2 sales.

The latest filing, published on 4 June 2026, reports an open-market sale of €9.3M in Nautilus Biotechnology, Inc. Most trades are made public on the day they happen. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.